NVP Abliva AB

Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP)

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP)

05-Oct-2018 / 11:14 GMT/BST

London, UK, 5 October 2018

Edison issues outlook on NeuroVive Pharmaceutical (NVP)

On 18 June 2018, NeuroVive (NVP:SS) announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a private biotech based in California, targeting Leber's Hereditary Optic Neuropathy (LHON) under new subsidiary Fortify Therapeutics. The upfront payment was limited, but the total deal value could reach $60m. NeuroVive is about to initiate a Phase Ib trial with the second lead drug candidate, KL1333 (NAD+ modulator), while both the EMA and FDA have provided positive views on the lead NeuroSTAT Phase IIb programme (TBI). We value NeuroVive at SEK1.64bn or SEK17.9/share.

Our updated valuation of NeuroVive is largely similar at SEK1.64bn or SEK17.9/share compared to SEK1.62bn or SEK17.7/share previously. The positive effect of rolling our model forward was partially offset by a lower net cash position. We maintain the R&D assumptions set out in our initiation report.

to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44(0)203 077 5728
Alice Nettleton, +44(0)203 077 5700


Learn more at and connect with Edison on:
LinkedIn
Twitter
YouTube


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

730645  05-Oct-2018 

fncls.ssp?fn=show_t_gif&application_id=730645&application_name=news&site_id=research_pool
EN
05/10/2018

Underlying

NVPAbliva AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abliva AB

 PRESS RELEASE
Free
NVP ABLIVA AB

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1...

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease - Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced...

July 18, 2024 1 EN
 PRESS RELEASE
Free
NVP ABLIVA AB

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Di...

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently n...

May 13, 2024 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - Termination of coverage

Edison Investment Research is terminating coverage on Abliva (ABLI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

03/01/23 March 1, 2023 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - IND approved by the FDA, preparing for Ph II/III

With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...

01/13/22 January 13, 2022 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - IND approved by the FDA, preparing for Ph II/III

With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...

01/13/22 January 13, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch